The advent of amyloid-β (Aβ) and tau PET imaging has revolutionized Alzheimer disease (AD) research, enabling in vivo ...

Radiotheranostics refers to dual diagnostic–therapeutic capacity that allows for precision medicine at an unprecedented level, reducing collateral toxicity and improving patient outcomes ([1][1]). In ...

In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Some of them have had a high clinical impact on the treatment of patients with ...

The results are presented as median and interquartile range (IQR) for continuous variables and as number and percentage for categoric variables. Kaplan–Meier analysis was used to estimate overall ...

Good-manufacturing-practice–grade precursor DOTA-Siglec-9 was obtained from ABX Advanced Biomedical Compounds GmbH. All other reagents were purchased from commercial suppliers and were either ...

Prostate cancer is the most common cancer diagnosis in men in the United States and a leading cause of cancer-related morbidity and mortality (1). It can exist along a wide spectrum of aggressiveness ...

SPECT is used to quantitatively and visually assess the distribution of radioactive biologic markers (tracers) in vivo in order to, for example, study animal models of disease and test new ...

Journal of Nuclear Medicine November 2025, jnumed.125.270568; DOI: https://doi.org/10.2967/jnumed.125.270568 ...

Pharmacokinetics of radiopharmaceuticals (e.g., radioimmunotherapy agents) are assumed to follow first-order kinetics and are, therefore, approximated by the sum of discrete rates (1–3). However, the ...

Neuroendocrine tumors (NETs) frequently form distant metastases and require systemic treatment (1). An established treatment option in advanced NETs is peptide receptor radionuclide therapy (PRRT) ...

TO THE EDITOR: Peptide receptor radionuclide therapy (PRRT) is highly effective in neuroendocrine tumors (NETs). In the NETTER-1 trial, progression-free survival at month 20 in patients with advanced ...

Because metabolic changes may precede changes in lesion morphology, there is growing interest in applying 18 F-FDG PET as an adjunct to anatomic imaging for the evaluation of chemotherapeutic response ...